Active Broker’s Choice in Focus: Whirlpool Corporation (NYSE:WHR), Regulus Therapeutics (NASDAQ:RGLS)

Shares of Whirlpool Corporation (NYSE:WHR) [Trend Analysis] runs in leading trade, it moving down -0.34% to traded at $174.31. The firm has price volatility of 3.30% for a week and 2.09% for a month. Its beta stands at 1.88 times. The seventh-largest public homebuilder in the United States, Meritage Homes has renewed its exclusive contract with Whirlpool Corporation (WHR) to feature Amana®, Whirlpool®, Maytag, KitchenAid and Jenn-Air brand appliances in its homes across the country. The four-year contract between Meritage, which has built more than 100,000 homes in its 31-year history, and the world’s leading manufacturer of major home appliances became effective June 1, 2016.

Meritage, which is based in Scottsdale, Ariz., builds and sells single-family homes for first-time, move-up, luxury and active adult buyers across the Western, Southern and Southeastern United States. In October, Meritage celebrated two major milestones: the delivery of its 100,000th home and unveiling LiVE.NOW™ homes that are focused on the rapidly growing first-time buyer market. Narrow down four to firm performance, its weekly performance was -6.46% and monthly performance was -4.33%. The stock price of WHR is moving down from its 20 days moving average with -4.88% and isolated negatively from 50 days moving average with -1.04%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) [Trend Analysis] luring active investment momentum, shares a loss -1.92% to $1.27. Bronstein, Gewirtz& Grossman, LLC is investigating potential claims on behalf of purchasers of Regulus Therapeutics Inc. (RGLS). The investigation concerns whether Regulus and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On June 27, 2016, Regulus reported that it had received notice from the U.S. Food and Drug Administration that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was declared. Following this news, Regulus dropped $2.47 per share, or over 49.3%, to close at $2.54 on June 28, 2016.

On January 27, 2017, post-market, Regulus revealed that the FDA would not reconsider the clinical hold on RG-101 until the agency had received the final safety and efficacy data from ongoing clinical and pre-clinical studies. Regulus notified investors that it expects the requested data to be accessible in the fourth quarter of 2017. The total volume of 342478 shares held in the session was surprisingly higher than its average volume of 703.24 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 15.70%, and looking further price to next year’s EPS is 8.40%. While take a short look on price to sales ratio, that was 5.73.

 

About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *